SRRK Apitegromab: $7.04B First SMA Add-On, Sept 30 PDUFA

Scholar Rock (SRRK) enters the final month before its September 30 PDUFA date at $57.80 a share and a $7.04 billion market cap. That number already assumes the FDA signs off on apitegromab, the first muscle-targeted therapy designed to layer on top of the three approved SMN drugs. The approval odds sit at better than 75%. The valuation is the problem. At $7.04 billion with zero revenue, Scholar Rock is worth 3.2x what the market pays for Sarepta, a company that books roughly $2.2 billion a year in muscle-disease revenue. This is a binary where the stock is pricing the win before the coin lands, and that is not an attractive entry.

Apitegromab is not another SMN gene therapy. Spinraza, Zolgensma, and Evrysdi all attack the root cause of spinal muscular atrophy by restoring or correcting the SMN protein. Apitegromab ignores SMN entirely. It is a monoclonal antibody that binds the pro and latent forms of myostatin, blocking the signal that tells skeletal muscle to stop growing. The thesis is that even after SMN therapy rescues the motor neurons, patients keep losing motor function because their muscles cannot hold onto what they have. Scholar Rock’s own numbers make the case: roughly 78% of SMA patients are already on an SMN drug, yet 95% of them still experience progressive muscle atrophy. Apitegromab is the add-on for that residual decline, which is why the company frames it as the second layer of the SMA stack rather than a fourth SMN competitor. The biology is validated broadly: Regeneron’s garetosmab, another antibody in the same activin and myostatin family, is already FDA-approved for fibrodysplasia ossificans progressiva, which tells you the muscle-directed mechanism works even though the field is getting crowded.

The registrational data is real, but it has a wrinkle that the bull case papers over. In the Phase 3 SAPPHIRE trial (NCT05156320), the primary analysis measured change in the Hammersmith Functional Motor Scale Expanded (HFMSE) score at 12 months in the main efficacy population of patients aged 2 to 12. The combined apitegromab arm, pooling the 10 mg/kg and 20 mg/kg doses (106 patients), beat placebo (50 patients) by 1.8 points with a p-value of 0.0192. The pooled 2-to-21-year analysis showed the same 1.8 point benefit with a 95% confidence interval of 0.46 to 3.16. The clinically meaningful responder rate, patients gaining more than 3 points on HFMSE, was 30.4% on apitegromab versus 12.5% on placebo. Those are solid results for a rare neuromuscular disease, and they cleared the confirmatory testing hierarchy the company agreed with the FDA.

The wrinkle is the dose. The 20 mg/kg dose alone, the one you would expect to commercialize, delivered a 1.4 point benefit versus placebo with a p-value of 0.1149, which is not statistically significant. The 10 mg/kg dose carried the trial with a 2.2 point benefit and p=0.0121. An FDA reviewer will see a registrational trial where the higher dose underperformed the lower dose, and they will ask whether the effect is real across doses or whether the label should be written narrowly. Scholar Rock’s management points to the combined result as the win, and by the letter of the SAPPHIRE design it is. But the 20 mg/kg miss is the number a skeptic will lean on, and it is why this approval should not be treated as a foregone conclusion.

The regulatory history cuts the other way. Scholar Rock received a Complete Response Letter in September 2025, but not for efficacy. The CRL was about observations at the Catalent Indiana fill-finish facility, a plant now owned by Novo Nordisk that carries an official action indicated classification. Scholar Rock resubmitted the BLA on March 30 with two fill-finish facilities, Catalent Indiana plus a second U.S. site that has since produced more commercial vials than Catalent. Management says it can drop Catalent entirely and proceed on the second facility alone with no impact to the timeline, and that the second facility has had pre-approval inspections waived across its last year of approvals. The Catalent classification is still pending, but the second facility gives Scholar Rock an independent path to a launch. This is why the approval odds sit above 75%: the clinical package cleared the bar, and the manufacturing overhang now has a workaround. The September PDUFA calendar lists apitegromab as one of the last genuine binary catalysts of the month, and the PDUFA trading playbook exists precisely for this kind of setup.

The market math is where caution is warranted. Scholar Rock targets the 35,000 SMA patients worldwide already on an SMN therapy, with the U.S. addressable population in the 10,000 to 15,000 range spread across roughly 140 treatment centers and 2,600 prescribing physicians. Apitegromab will launch as a chronic biologic layered on top of therapies that already cost hundreds of thousands of dollars a year. If it prices near $150,000 annually and captures a meaningful slice of the U.S. add-on market over several years, peak sales land somewhere in the $1 billion to $2 billion range. At $7.04 billion, the market is paying roughly four times the low end of that peak sales range for a drug that has not been approved yet. That is priced for perfection.

The comparison that stands out is Sarepta. Sarepta (SRPT) booked $2.2 billion in 2025 revenue, including $899 million from ELEVIDYS, its DMD gene therapy. It trades at a $2.2 billion market cap today, about 1x sales, after suspending ELEVIDYS shipments to non-ambulatory patients in June 2025 and watching revenue fall 34% year over year in the second quarter. So the market values a company with $2.2 billion in actual muscle-disease revenue at $2.2 billion, and values a pre-approval company with zero revenue at $7.04 billion. Either apitegromab is a dramatically better asset than ELEVIDYS, or Scholar Rock is overpriced relative to the muscle-disease comp. It is mostly the latter. Both companies own one muscle-directed product in a field where a safety scare or a reimbursement snag can crater a stock in a single quarter, and the Sarepta chart is the cautionary tale for anyone paying up ahead of a muscle-therapy launch.

The 20 mg/kg miss is the risk that matters. If the FDA writes the label around the lower dose or attaches a post-marketing confirmatory requirement, the launch ramp gets squeezed before it starts. The balance sheet tightens the timeline: $492 million in cash against roughly $110 million in quarterly net losses means any delay forces another at-the-market raise. And even on a clean label, launch execution is slow by design. Scholar Rock’s own COO told analysts that for the first six months, before a J-code is assigned, the average time from prescription to infusion will exceed 60 days because nearly every patient faces a prior authorization and most draw an initial denial, a reimbursement drag baked into the first two quarters.

The verdict is a small position, not a full one. The approval is likely because the clinical package cleared and the manufacturing fix has a workaround, and one to two percent of a diversified biotech book is a reasonable way to own the optionality through the September 30 decision. But at $7.04 billion, do not size it like a slam dunk. A clean broad label probably re-rates the stock toward $9 billion to $10 billion as the launch gets a clear runway. A restricted label or a Catalent classification blowup sends it down 30% to 40%, because the stock is already priced for the best case. At $57.80 the risk-reward is roughly symmetric, and symmetry is not a reason to go big. It is better to see the label before paying up, and if you must own it ahead of the PDUFA, keep it small and treat it as a coin flip with a house edge, not an approval locked in.